Miragen Therapeutics Inc (MGEN) Buy Rating Maintained Today By B.Riley FBR; The Target Price per Share is Set to $18.5000

May 18, 2018 - By Jason Grubb

Miragen Therapeutics Inc (MGEN) Rating Reaffirmed

In analysts note sent to investors this morning, B.Riley FBR reiterated their Buy rating on Miragen Therapeutics Inc (MGEN) shares. The target would indicate a possible upside of 148.99 % from company’s current price.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering miRagen Therapeutics Inc (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. miRagen Therapeutics Inc has $19.0 highest and $1300 lowest target. $16.29’s average target is 119.25% above currents $7.43 stock price. miRagen Therapeutics Inc had 17 analyst reports since December 1, 2017 according to SRatingsIntel. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Wednesday, March 28 by Wedbush. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Thursday, March 15 by FBR Capital. Oppenheimer initiated the stock with “Buy” rating in Thursday, January 11 report. Wedbush maintained Miragen Therapeutics, Inc. (NASDAQ:MGEN) rating on Monday, April 30. Wedbush has “Buy” rating and $1900 target. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Tuesday, March 27 by FBR Capital. Wedbush maintained it with “Buy” rating and $19.0 target in Tuesday, March 20 report. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) earned “Buy” rating by Wedbush on Friday, December 1. The rating was maintained by FBR Capital on Friday, February 2 with “Buy”. The rating was maintained by Wedbush with “Buy” on Monday, April 23. Oppenheimer initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Tuesday, March 27 with “Buy” rating.

The stock decreased 1.07% or $0.08 during the last trading session, reaching $7.43. About 178,818 shares traded. Miragen Therapeutics, Inc. (MGEN) has declined 43.43% since May 18, 2017 and is downtrending. It has underperformed by 54.98% the S&P500.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on August, 10. They expect $-0.26 EPS, up 23.53 % or $0.08 from last year’s $-0.34 per share. After $-0.18 actual EPS reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 44.44 % negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $224.33 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Streetinsider.com which released: “miRagen Therapeutics (MGEN) to Highlight New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis …” on May 09, 2018, also Nasdaq.com with their article: “miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and …” published on April 27, 2018, Seekingalpha.com published: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Nasdaq.com and their article: “miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for …” published on April 19, 2018 as well as Nasdaq.com‘s news article titled: “miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” with publication date: May 09, 2018.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: